Related Experiment Video
Updated: Jan 17, 2026

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
Published on: October 5, 2020
ELOVL6 activity attenuation induces mutant KRAS degradation
Xiyue Hu1, Ranjit Singh Atwal1,2, Sophie Xiao1
1Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Abstract:
KRAS is one of the most frequently mutated oncogenes in cancer. Targeting mutant KRAS directly has been challenging because of minor structural changes caused by mutations. Despite recent success in targeting KRAS-G12C, targeted therapy for another hotspot mutant, KRAS-G12V, has not been described. We used CRISPR-Cas9 genome-wide knockout screens to identify genes that specifically modulate mutant KRAS harboring the G12V substitution. Our top hit, a fatty acid elongase (ELOVL6), showed remarkable selectivity in diminishing KRAS-G12V protein expression and aberrant oncogenic signaling associated with mutant KRAS. Our studies reveal that ELOVL6 can be targeted to control the production of phospholipids exploited by KRAS mutants for function-targeted and trigger-targeted degradation of the protein. Our results demonstrate the basis for a first-in-class small-molecule inhibitor to selectively clear KRAS-G12V from cancer cells.
Insights
Researchers identified fatty acid elongase 6 (ELOVL6) as a key target to reduce KRAS-G12V oncoprotein in cancer. This discovery paves the way for new KRAS-G12V-specific cancer therapies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- KRAS mutations are common in cancer, but targeting them is difficult due to subtle structural changes.
- While KRAS-G12C is targeted, effective therapies for KRAS-G12V remain elusive.
- Identifying specific vulnerabilities of KRAS-G12V is crucial for developing new cancer treatments.
Purpose of the Study:
- To identify genes that specifically modulate the KRAS-G12V mutant.
- To explore ELOVL6 as a potential therapeutic target for KRAS-G12V-driven cancers.
- To understand the mechanism by which ELOVL6 affects KRAS-G12V.
Main Methods:
- CRISPR-Cas9 genome-wide knockout screens were employed to identify modulators of KRAS-G12V.
- Protein expression levels and oncogenic signaling pathways were analyzed.
- Phospholipid production pathways were investigated in relation to KRAS-G12V function.
Main Results:
- ELOVL6 was identified as a top hit, selectively reducing KRAS-G12V protein expression.
- Targeting ELOVL6 diminished aberrant oncogenic signaling driven by KRAS-G12V.
- ELOVL6 was found to regulate phospholipid production essential for KRAS-G12V function.
Conclusions:
- ELOVL6 is a promising therapeutic target for KRAS-G12V-mutated cancers.
- Targeting ELOVL6 can lead to the degradation of KRAS-G12V oncoprotein.
- This research provides a foundation for developing novel small-molecule inhibitors against KRAS-G12V.
More Related Videos
Related Concept Videos
The Ras Gene
Ras is a...
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
Export of Misfolded Proteins out of the ER

